Oruka Therapeutics Finalizes Upsized $700.35M Public Offering at $72.50 Per Share

summarizeSummary

Oruka Therapeutics has finalized its upsized public offering, raising $700.35 million in gross proceeds by selling 9.66 million shares at $72.50 per share, following recent positive clinical trial data.

check_boxKey Events

• Offering Finalized and Upsized

  This filing confirms the final terms and pricing of the public offering, which was upsized from a proposed $500 million to $700.35 million in gross proceeds.

• Significant Capital Infusion

  The company will receive approximately $658.3 million in net proceeds, substantially strengthening its balance sheet for future operations.

• Strategic Pricing Achieved

  Shares were priced at $72.50, which is a premium to the current market price of $68.00, indicating strong investor demand following recent positive clinical data.

• Dilution Impact

  The offering of 9.66 million shares will result in approximately 19.83% dilution to existing shareholders based on shares outstanding as of December 31, 2025.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of the public offering, which was previously announced as a proposed $500 million offering. The company successfully upsized the offering to $700.35 million in gross proceeds, securing approximately $658.3 million in net proceeds. This substantial capital infusion significantly strengthens Oruka Therapeutics' financial position, providing crucial funding for general corporate purposes, including research and development. The offering was priced at $72.50 per share, which is a premium to the current market price of $68.00, indicating strong institutional demand and confidence, especially following the highly positive Phase 2a clinical trial results for ORKA-001 announced on April 27, 2026. While the offering is dilutive, increasing outstanding shares by approximately 19.83%, securing this level of funding at a favorable price is a critical de-risking event for a clinical-stage biopharmaceutical company to advance its pipeline and extend its operational runway.